Since early 1990s, 5-ALA was started being used into photodynamic diagnosis and therapy for skin, oral, bladder and gastrointestinal tumours. After then, several research groups have found 5-ALA induced porphyrin can be accumulated with high fluorescence in experimental malignant gliomas in vitro and in vivo, which would help to distinguish the viable and rapidly proliferating tumour margins intraoperatively and therefore improve the extent of resection (EOR). In 1998, Stummer et al. has firstly introduced 5-ALA into intraoperative detection of malignant gliomas with 9 patients . In 2000, a prospective study involving 52 patients was carried out by Stummer et al. using 5-ALA induced porphyrins for fluorescence-guided resection of glioblastoma multiforme . In 2006, Stummer et al. reported a randomised controlled multicentre phase III trial on fluorescence-guided surgery had been done with 5-ALA for resection of malignant glioma. With the clinical data collected from 322 patients enrolled in this trail, it was demonstrated that 5-ALA induced fluorescence guided surgery can be really beneficial for patients, in terms of completeness of tumour removal and progression-free survival .